Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Open Life SciencesOpen Access

Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJiawen ZhangAssociation for the Development of Earthquake PredictionLXLei XuChina Agricultural UniversityCSCaifeng SunNanjing Maternity and Child Health Care Hospital

Discussion

Loading...

Member takes

Overview

Meta-analysis shows PD-1/PD-L1 inhibitors improved outcomes in R/R DLBCL patients, suggesting combined therapies may enhance efficacy.

Key Points

  • PD-1/PD-L1 inhibitors demonstrated an overall suboptimal efficacy in treating relapsed refractory DLBCL patients, emphasizing the need for improvement.
  • The estimated complete response rate was found to be OR = 0.21 with a statistically significant p value < 0.001, indicating limited therapeutic response.
  • Combining PD-1/PD-L1 inhibitors with CAR-T therapy could lead to enhanced treatment outcomes, showing promise for future therapies.
  • Patients tolerated PD-1/PD-L1 inhibitors well, with estimated grade 3 adverse events at OR = 0.33 and p = 0.01, confirming safety in administration.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68c1b61454b1d3bfb60eb67fhttps://doi.org/10.1515/biol-2025-1129
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,103 citations
  2. 2Immune evasion in cancer: Mechanistic basis and therapeutic strategies2015 · 1,685 citations
  3. 3Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation2019 · 45 citations
  4. 4Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation2000 · 5,288 citations
  5. 5Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,641 citations